Literature DB >> 3807893

[3H]acetylcholine and [3H](-)nicotine label the same recognition site in rat brain.

A M Martino-Barrows, K J Kellar.   

Abstract

High affinity binding sites for [3H]acetylcholine and [3H](-)nicotine in rat brain were compared with respect to key characteristics, any one of which should distinguish them if they are different. The density of binding sites for each ligand varied approximately 4-fold in five areas of rat forebrain, but in each of these areas and in human cerebral cortex as well, the densities of [3H]acetylcholine- and [3H](-)nicotine-binding sites were indistinguishable. The affinity of [3H](-)nicotine was higher than that of [3H]acetylcholine, but nicotinic cholinergic drugs competed for the sites labeled by the two ligands with similar affinities; and in each case, the site labeled displayed marked stereoselectivity for the enantiomers of nicotine. The binding of [3H]acetylcholine and [3H](-)nicotine was decreased to the same extent by preincubation of tissues with dithiothreitol, and the binding was restored by subsequent treatment with 5,5'-dithiobis-2-nitrobenzoic acid, indicating that a disulfide bond is required at or near the binding site for each ligand. Treatment of rats with nicotine for 10 days increased the density of binding sites for both ligands, and treatment with the cholinesterase inhibitor soman for 9 days decreased the density of binding sites for both ligands. Taken together, these results indicate that [3H]acetylcholine and [3H](-)nicotine bind to the same nicotinic cholinergic recognition site in rat brain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3807893

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

Review 1.  Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine.

Authors:  E L Ochoa; L Li; M G McNamee
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

Review 2.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

3.  Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices.

Authors:  R E Loiacono; F J Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

4.  Characterization of human alpha4beta2 neuronal nicotinic receptors stably expressed in SH-EP1 cells.

Authors:  M A Pacheco; T E Pastoor; R J Lukas; L Wecker
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

5.  Characterization of nicotinic acetylcholine receptors on cultured bovine adrenal chromaffin cells using modified L-[3H]nicotine binding assay.

Authors:  K Lee; S Miwa; K Koshimura; A Ito
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

Review 6.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

Review 7.  Nicotine-related brain disorders: the neurobiological basis of nicotine dependence.

Authors:  E L Ochoa
Journal:  Cell Mol Neurobiol       Date:  1994-06       Impact factor: 5.046

8.  In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice.

Authors:  M I Damaj; S P Welch; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  Nicotine tolerance: an analysis of the time course of its development and loss in the rat.

Authors:  A C Collins; E Romm; J M Wehner
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes.

Authors:  Michael J Marks; Duncan S Laverty; Paul Whiteaker; Outi Salminen; Sharon R Grady; J Michael McIntosh; Allan C Collins
Journal:  J Mol Neurosci       Date:  2009-08-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.